CNSP Stock — CNS Pharmaceuticals Inc

CNS Pharmaceuticals Inc (CNSP)

Updated October 16, 2026.

CNSP is a Stock. Total return is -100.0% over the past 6.9 years, 273.1 points behind SPY at 173.1%.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing therapies for neurology and oncology diseases, with lead candidates including TPI 287 and Berubicin in Phase II trials for conditions such as glioblastoma, metastatic breast cancer with brain metastases, and other cancers. The company does not currently distribute income to shareholders. CNS Pharmaceuticals appeals to investors seeking exposure to early-stage drug development with potential for significant gains if clinical trials succeed, though such investments carry substantial development and regulatory risk.

CNSP performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 6.9 years, 273.1 points behind SPY at 173.1%. Over the past year its total return — price change plus distributions reinvested — is -48.9%. Its deepest 1-year drawdown was 77.6%.

CNSP key facts

Asset type

Stock

Asset class

Equity

Inception date

11/08/2019

Distribution frequency

None

Last close

$4.85 (as of 2026-10-16)

Market cap

$7,089,489

Average volume

13230.0

Beta

1.018

Payout ratio

0.0%

EPS

$-18.45

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CNSP risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 77.6%.

Who may consider CNSP — and who may not

It is a weaker fit for investors who need monthly cash flow (CNSP does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CNSP

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions